eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Fertility, pregnancy and lactation


There are no data from the use of ELIQUIS in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity.

ELIQUIS is not recommended during pregnancy.


It is unknown whether ELIQUIS or its metabolites are excreted in human milk. Available data in animals have shown excretion of ELIQUIS in milk. In rat milk, a high milk-to-maternal-plasma ratio (Cmax about 8, AUC about 30) was found, possibly due to active transport into the milk. A risk to newborns and infants cannot be excluded.

A decision must be made to either discontinue breastfeeding or to discontinue / abstain from ELIQUIS therapy.


Studies in animals dosed with ELIQUIS have shown no effect on fertility.


Stay on top of ELIQUIS product updates

Download guides designed for your patients

Access further resources, including treatment guidelines, patient materials and downloadable supporting materials

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

AUC = Area Under the Curve


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.